TY - JOUR
T1 - Effect of risedronate on bone in renal transplant recipients
AU - Coco, Maria
AU - Pullman, James
AU - Cohen, Hillel W.
AU - Lee, Sally
AU - Shapiro, Craig
AU - Solorzano, Clemencia
AU - Greenstein, Stuart
AU - Glicklich, Daniel
PY - 2012/8
Y1 - 2012/8
N2 - Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.
AB - Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.
UR - http://www.scopus.com/inward/record.url?scp=84864834951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84864834951&partnerID=8YFLogxK
U2 - 10.1681/ASN.2011060623
DO - 10.1681/ASN.2011060623
M3 - Article
C2 - 22797188
AN - SCOPUS:84864834951
SN - 1046-6673
VL - 23
SP - 1426
EP - 1437
JO - Journal of the American Society of Nephrology
JF - Journal of the American Society of Nephrology
IS - 8
ER -